ID   MM170
AC   CVCL_2603
SY   MM 170
DR   BioSample; SAMN07624424
DR   cancercelllines; CVCL_2603
DR   CBA; CBA-1346
DR   Cosmic; 889013
DR   Cosmic; 928712
DR   ECACC; 10092315
DR   GEO; GSM162905
DR   Wikidata; Q54906067
RX   PubMed=294576;
RX   PubMed=460945;
RX   PubMed=830403;
RX   PubMed=1697409;
RX   PubMed=6187441;
RX   PubMed=9354451;
RX   PubMed=10070891;
RX   PubMed=15048078;
RX   PubMed=17516929;
RX   PubMed=22383533;
RX   PubMed=23039341;
CC   Problematic cell line: Contaminated. Presence of a second cell line in earliest stock not picked up due to low level of contamination (CBA=CBA-1346).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533).
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: CBA; CBA-1346; true.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): CBA
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,9
ST   D16S539: 10,12
ST   D18S51: 13,17
ST   D19S433: 14
ST   D21S11: 28,31.2
ST   D2S1338: 20,24
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 13,14
ST   FGA: 22,25
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 18,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 22
//
RX   PubMed=294576; DOI=10.3109/00313027909059039;
RA   Muir P.D., Gunz F.W.;
RT   "A cytogenetic study of eight human melanoma cell lines.";
RL   Pathology 11:597-606(1979).
//
RX   PubMed=460945; DOI=10.3109/00313027909061945;
RA   Pope J.H., Morrison L.E., Moss D.J., Parsons P.G., Dunne R.M.;
RT   "Human malignant melanoma cell lines.";
RL   Pathology 11:191-195(1979).
//
RX   PubMed=830403;
RA   Goss P.D., Parsons P.G.;
RT   "The effect of hyperthermia and melphalan on survival of human
RT   fibroblast strains and melanoma cell lines.";
RL   Cancer Res. 37:152-156(1977).
//
RX   PubMed=1697409;
RA   Chenevix-Trench G., Martin N.G., Ellem K.A.O.;
RT   "Gene expression in melanoma cell lines and cultured melanocytes:
RT   correlation between levels of c-src-1, c-myc and p53.";
RL   Oncogene 5:1187-1193(1990).
//
RX   PubMed=6187441;
RA   Parsons P.G., Musk P., Goss P.D., Leah J.;
RT   "Effects of calcium depletion on human cells in vitro and the
RT   anomalous behavior of the human melanoma cell line MM170.";
RL   Cancer Res. 43:2081-2087(1983).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=10070891; DOI=10.1038/sj.bjc.6690147;
RA   Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.;
RT   "p53 mutations in human cutaneous melanoma correlate with sun exposure
RT   but are not always involved in melanomagenesis.";
RL   Br. J. Cancer 79:921-926(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
//